Siltuximab
Castleman Disease
Centocor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Castleman Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab M.D. Anderson Cancer Center | Phase 1 | CC |
Temsirolimus M.D. Anderson Cancer Center | Phase 1 | CC |
Valproic Acid M.D. Anderson Cancer Center | Phase 1 | CC |
Silmitasertib Cylene Pharmaceuticals | Phase 1 | CC |
Nelfinavir Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early Phase 1 | C |
Same molecule, other indications
Siltuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →